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SUMMARY – Amyotrophic lateral sclerosis is a progressive and fatal degenerative neuromuscular 
disease with few if any treatment options and physical rehabilitation addressing specific deficits is the 
most frequent form of therapy. Patients also suffer from depression and increased anxiety. Our purpose 
was to assess the neurorehabilitation effectiveness in a patient with amyotrophic lateral sclerosis who 
underwent stem cell transplantation but refused physiotherapy due to depression. Disease progression 
was followed using the revised Amyotrophic Lateral Sclerosis Functional Rating Scale bimonthly for 
six months pre- and then post-stem cell transplantation. Psychological traits were assessed using six 
standardized tests. Quantitative electroencephalogram diagnostics was performed before the first and 
after the last neurofeedback session, and sessions were conducted on a 3-times-a-week basis. The 
physiotherapy protocol included proprioceptive neuromuscular facilitation, electrical modalities unit 
applied to the lumbar spine area, and breathing, relaxation and walking exercises, among others. In-
creased motivation and marked decrease in the pain level was associated with the patient’s willingness 
to complete physiotherapy, which resulted in improvements in most neuromuscular deficits and in 
increased respiratory capacity. During the 12 post-rehabilitation months, progression of the disease 
decelerated, and a positive behavioral change was noted. The study suggested that neurofeedback 
could be used as a neurorehabilitation component of the personalized complex rehabilitation protocol 
in patients with amyotrophic lateral sclerosis.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a degenera-
tive neuromuscular disorder characterized by progres-
sive loss of both upper motor neurons in the primary 
motor cortex and lower motor neurons in the brain-
stem and spinal cord. Initial symptoms of ALS include 
muscle atrophy and weakness, often followed by 
spreading paralysis of the voluntary muscles, and even-
tually the respiratory muscles1. The disease is typically 
fatal within 2-5 years of symptom onset, whereas about 
10% of patients may survive for more than a decade2,3. 
There are currently few if any treatment options, early 
detection or prevention methods are not yet available, 
and rehabilitation treatments addressing specific needs 
and deficits are the most frequent form of therapy 
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available to most of ALS patients4. However, rehabili-
tation results vary due to the complexity of ALS, broad 
spectrum of presentation and disease progression rate, 
and development of individualized, complex rehabili-
tation protocols is recommended5-9.
Patients with ALS also suffer from an additional 
burden of heavy neuropsychological deficits and im-
balances, most prominently of depression and elevated 
anxiety10,11, and have impaired executive functions and 
social cognition skill tasks12. Therefore, there is an ur-
gent need for investigation of methods supplementing 
individual treatments and rehabilitation protocols that 
would modify psychological factors to improve the 
quality of life11.
One of the potential companion therapies could be 
electroencephalogram neurofeedback (EEG NFB), 
neurophysiotherapy and rehabilitation method which 
employs interaction between the patient’s mental state 
and brain activity, allowing patients to be actively and 
consciously involved in controlling their own neuro-
physiological processes13,14. Through the evidence-
based practice, NFB is gaining attention as a method 
which has been successfully applied to a wide spec-
trum of brain-related disorders15, most prominently 
anxiety16, sleep quality and insomnia16, reducing post-
operative pain18, epilepsy19,20 and stroke21.
In the last several years, a substantial progress has 
been made in developing methods and protocols em-
ploying various stem cell types targeting neurodegen-
erative disorders for single and multiple stem cell 
transplantations (SCT), and the long-term effects of 
SCT are anxiously awaited22-27. Taking into account 
these recent progresses, there is the need to continue 
designing individual complex rehabilitation strategies 
and to report successful approaches that may improve 
both the SCT efficacy and the quality of life in ALS.
This report describes evaluation of the NFB effec-
tiveness in the assessment and therapy of cognitive 
dysfunction, motivation and mood disorders in a 
71-year-old patient presenting with ALS who under-
went subdural stem cell implantation, but initially re-
fused individually designed rehabilitation. The poten-
tial of the NFB as a companion therapy in rehabilita-
tion of ALS patients is discussed.
Patient and Methods
The patient was a 71-year-old male who first pre-
sented in 2007 with discopathy of the cervical and 
lower lumbar segments, benign prostatic hyperplasia, 
and vitamin B12 deficiency, and had been treated with 
nonsteroidal anti-inflammatory drugs and vitamin 
B12 supplementation. Continuous assistance of a third 
person was at some point required, and in 2012 the 
patient was diagnosed with the flail arm syndrome, a 
variant of ALS, meeting the El Escorial diagnostic cri-
Fig. 1. ALSFRS-R scores reported bimonthly for patient during pre- [1b-4b] and post- [1a-4a] stem cell 
transplantation period. Arrow indicates the stem cell transplantation time point. The 12 ALSFRS-R scored tasks are 
listed in the inset, with color shades grouped according to the activity types. The [pt/period] indices represent total 
bimonthly ALSFRS-R changes in the pre- [1b-4b] and post- [1a-4a] stem cell transplantation period.
ALSFRS-R = Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
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teria28. Noninvasive ventilation became necessary (8 h 
at night and 1-2 h during the day). Fasciculations were 
present at multiple sites including muscles of the up-
per and lower extremities, and right-side Babinski’s 
sign, dystrophy of the chest musculature and muscular 
dystrophy of the upper limb girdle were confirmed. 
The patient also presented elevated blood pressure and 
ischemic cardiovascular disease, and his respiratory in-
sufficiency was diagnosed as the chronic obstructive 
pulmonary disease (COPD). Despite supplementa-
tion, the patient was continuously showing vitamin 
B12 deficiency. Brain magnetic resonance imaging 
(MRI) showed small areas of cortical atrophy, and 
electromyography indicated distal median nerve injury 
and injury of the motor neurons of the anterior horns 
of the spinal cord at the C5/C6, C8-Th1, L2-L4, L5-
S1 levels, with the features of right upper limb dener-
vation. During his 8-day hospitalization, the patient 
had physiotherapy sessions which he tolerated very 
well. At the time of discharge, the patient was recom-
mended to the ambulatory care to continue physio-
therapy. Noninvasive ventilation was to be adjusted to 
his needs. Three arms of medications were adminis-
tered, as follows: (1) Rilutek, and medications to con-
trol (2) ischemic cardiovascular disease and high blood 
pressure, and (3) COPD.
Three years later, the patient was referred to the 
Neurological Department, University Hospital in Ol-
sztyn, and his disease status was assessed using the re-
vised version of the ALS Functional Rating Scale-Re-
vised (ALSFRS-R). The scale includes 12 questions, 
where each task is rated on a five-point scale from 
0=can’t do to 4=normal ability, and the individual item 
scores are summed to produce a reported score between 
0=worst and 48=best. The score obtained at the first 
evaluation was 33, as shown in Figure 1, and after ad-
ditional examination the patient was considered a can-
didate for the Wharton’s jelly-derived mesenchymal 
stem cell transplantation24,26. To determine individual 
rate of ALS progression and then the outcome of the 
SCT followed by complex rehabilitation, the disease 
status was assessed using ALSFRS-R bimonthly for six 
months prior to the SCT, and then every two months 
post-transplantation. After six months, it was deter-
mined that the criteria for SCT set in the Protocol Nr 
32/2013 of the Bioethical Committee at the Faculty of 
Medical Sciences, University of Warmia and Mazury 
in Olsztyn were fulfilled, the patient provided his writ-
ten informed consent, and 1.8x107 stem cells were ad-
ministered into the subdural space. Following a 12-day 
postoperative period, the patient was admitted to the 
clinical rehabilitation center for complex physical and 
neurological rehabilitation.
At the time of admission, physical examination 
showed tetraparesis with resultant minor distal weak-
ness, more pronounced in the left limbs, extensive 
muscular dystrophy of the upper limb girdle and dys-
trophy of limb musculature, limited precision of finger 
movements, overall lower muscle strength, extensive 
fasciculations in the upper body, limited mobility of 
cervical and lumbar spine, grade 1 right side scoliosis 
of the thoracolumbar spine, lowered respiratory capac-
ity and lower exercise endurance. The patient com-
plained of severe pain in the extensive spinal area and 
joints (9/10 points on the visual analog scale, VAS). 
During the six-minute walk test (6MWT), the patient 
walked 192 meters with the help of a standard walker, 
and the Balance + Gait score of the Tinetti Gait and 
Balance Assessment Tool29 was 16/28.
Psychological evaluation revealed multiple cognitive 
deficits and moderate depression. The patient’s psycho-
logical and personality traits were assessed using a series 
of standardized tests including Spielberg State-Trait 
Anxiety Inventory, Eysenck Personality Questionnaire, 
The Hamilton Rating Scale for Depression, Common 
Task Test, Addenbrooke’s Cognitive Examination – Fi-
nal Revised Version, and the Raven Matrices Test. The 
goals of the tests and the results obtained are shown in 
Table 1. It was determined that the patient suffered 
from increased anxiety, had a conscious feeling of fear, 
guilt and stress, and showed increased intensity of neu-
roticism, extraversion and psychoticism. The patient also 
demonstrated irritability, low mood and depression, im-
paired abilities to plan and perform more complex tasks, 
impaired cognitive and sequential information-process-
ing abilities, and deterioration of attention/orientation, 
memory, verbal fluency and visuospatial abilities. The 
interview with his family members using The Informant 
Questionnaire on Cognitive Decline in the Elderly 
Questionnaire revealed a decline of memory and execu-
tive/decision making functions at an average level as 
compared to the overall patient’s functioning 10 years 
before.
Following examinations, an individual experimen-
tal physiotherapy protocol was developed taking into 
account specific patient deficits and needs. Types and 
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schedules of exercises are listed in Table 2. Special at-
tention was paid to the exercise sessions including pro-
prioceptive neuromuscular facilitation, passive stretch-
ing of shoulder joints, as well as passive and progres-
sive resistive exercises of lower extremities, manual 
therapy including classic massage techniques to shoul-
der girdle and upper extremity musculature, electrical 
modalities including Transcutaneous Electrical Nerve 
Stimulation unit applied to the lumbar spine area, 
breathing and relaxation exercises, vestibular exercises, 
and walking training using a standard walker. All exer-
cises were to be carried out under supervision of a 
physician-physiotherapist, who also had daily Mon-
day-Saturday consultations with the patient.
However, the mobility exercises were initially very 
difficult to carry out due to the patient’s low mood and 
Table 1. Assessment of the patient’s psychological and personality traits prior to rehabilitation
Assessment goal Results Conclusions
STAI - Spielberger State-Trait Anxiety Inventory 
Measure of trait and 
state anxiety
Anxiety as a trait - sten 
7/10,
Anxiety as a state - sten 
4/10
Moderate tendency to perceive minor threatening situations as 
serious endangerments and reaction to these with anxiety and 
fear, which indicates that this patient did not suffer earlier from 
an anxious personality disorder. In the current situation, 
however, the patient suffers from elevated anxiety and conscious 
feeling of fear and stress, with accompanying activation of the 
autonomic nervous system. 
Eysenck Personality Questionnaire (EPQ)




Psychoticism 4/10,  
Lie 6/10,  
Agreeableness 5/10
Moderate increase in intensity of neuroticism, extraversion, 
psychoticism, agreeableness, tendency to lie.
Hamilton Rating Scale for Depression (HRS)
Mood and depression 
assessment 
Score: 17/58 Low mood, moderate depression. 
Common Task Test 
Executive functions CTT1 - ten 43/100; 
CTT2 - ten 31/100
Impaired abilities to plan and perform more complex tasks; lack 
of focus on the external stimuli; low resistance to distraction; 
impaired attention types: sustained, divided and alternating; 
impaired cognitive and sequential information-processing 
abilities.
ACE-R Addenbrooke’s cognitive examination - Final Revised Version
Assessment of 
attention/orientation, 









Deterioration of attention/orientation, memory, verbal fluency 








Assessment of patient’s 
functioning compared 
with 10 years before
Decline of memory and executive/decision making functions at the average level as 
compared to the overall patient’s functioning 10 years before was established during the 
interview with his family members.
Joanna Białkowska et al. Complex treatment of ALS patient
Acta Clin Croat, Vol. 58, No. 4, 2019 761
progressing depression, and his refusal to continue the 
given task. His communication with the rehabilitation 
facility staff became increasingly more difficult. At this 
point, a decision was made to implement electroen-
cephalogram neurofeedback (EEG NFB) therapy. The 
general principles and goals of the NFB training were 
explained to the patient and he agreed with this ap-
proach.
A quantitative electroencephalogram (QEEG) di-
agnostics performed prior to the EEG NFB therapy 
assessed the effect of the neurofeedback method on 
the neurophysiological parameters in the EEG record-
ing of the b, b2, waves, sensorimotor rhythm (SMR) 
and t waves. The first test demonstrated dominance of 
the SMR activity (12-15 Hz) and b waves (15-20 Hz) 
in the left brain hemisphere (b waves were correct, and 
SMR was incorrect), which was consistent with emo-
tional imbalance and attention deficits. The d waves 
(1-3 Hz) and t waves (4-8 Hz) in the central region 
slightly exceeded the norm of 20 and 10 µV, respec-
tively. Amplitudes of a waves (9-12 Hz) were consid-
ered normal. The b2 waves (20-34 Hz) for the leads in 
C3 and C4 were above normal. Both elevated b2 am-
plitudes were consistent with emotional tension, fear 
and mood imbalances. Amplitude values observed in 
the C, F, Fp, P and O leads using the QEEG analyses 
are presented in Figure 2. The NFB sessions were de-
signed to create optimal conditions for the patient's 
mental functioning, to achieve the state of simultane-
ous relaxation and alertness intended to improve ther-
apy for memory function, attention and concentration, 
and to induce motivation to continue physical therapy. 
The difficulty level of each of the training sessions was 
set based on the patient's individual ability, and the 
length of therapy was established taking into account 
his personal needs. The training was conducted in a 
cycle of 10 sessions, on a regular 3-times-a week basis. 
The time designated to one training session was 30 
min. The patient underwent classic C3:C4 training 
(b/t:SMR/t) with classic frequency settings. The feed-
back sound was set at 150-200 ms. Rewarding the pa-
tient with the visual and sound program effects to in-
crease the sensorimotor waves (13-15 Hz) along the 
sensorimotor strip was designed to reduce his impul-
sive behavior and to induce more frequent reflection 
prior to undertaking an action. According to Ster-
man30, strengthening the SMR waves increases the 
body’s ability to maintain homeostasis, and activates 
alertness and relaxation. In the case described here, 
during the training with the activities in the 12-15 Hz 
Table 2. Experimental physiotherapy protocol developed for rehabilitation following stem cell transplantation
Type of exercises Schedule of exercises
Proprioceptive Neuromuscular Facilitation (PNF) 1x daily, 6x per week, 30 min sessions
Passive stretching exercises of shoulder joints, as well as 
passive and progressive resistive exercises of lower extremities
1x daily, 6x per week, 30 min sessions
Manual therapy including classic massage techniques to 
shoulder girdle and upper extremity musculature
1x daily, 6x per week, 30 min sessions
Trigger point therapy 1x daily, 3x per week, 20 min sessions
Manipulative techniques 1x daily, 6x per week, 30 min sessions
Electrical modalities including TENS unit applied to the 
lumbar spine area
1x daily, 6x per week, 20 min sessions, 15 days 
Laser applied to painful areas, shoulder girdle and lumbar 
spine area
1x daily, duration: 3 min., 6x per week, 20 days 
Warm gel compresses applied to painful areas including 
shoulder joints 
1x daily, every day, 2x20 min
Breathing and relaxation exercises 1x daily, 6x per week, 1x20 min
Vestibular exercises 1x daily, 6x per week, 1x20 min
Walking training using standard walker 3x daily, training duration depending on patient 
condition and willingness, starting with 5 min, 
gradually increasing to 3x20 min daily
Unless otherwise stated, all types of exercises listed were carried out throughout the 30-day rehabilitation period
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range, the active electrode was placed in C4. The goal 
was to lower the amplitude and percent contribution 
of the t waves (4-8 Hz) and b2 waves (frequency above 
18 Hz), to reduce the patient's emotional imbalances, 
elevated anxiety, and akathisia/psychomotor restless-
ness.
Results
After the first three NFB sessions, there was clear 
improvement in the patient’s mood and cooperation 
with therapists, and his interest in continuing physical 
therapy exercises at the planned schedule significantly 
increased. As the result, the entire rehabilitation proto-
col including NFB sessions was performed as initially 
designed. After 10 training sessions, an increase in the 
amplitude of the SMR waves was achieved in the right 
hemisphere, and the intended reduction of the b waves 
was obtained. The pre- versus post-treatment changes 
in the amplitudes of the given waves for the respective 
leads in the QEEG analyses are shown in Figure 2, 
and the pre- versus post-treatment changes in the am-
plitudes of SMR waves in Figure 3.
The complex rehabilitation therapy described above 
resulted in marked improvement of muscle strength in 
the upper and lower extremities and in the postural 
muscles. The balance, motion coordination and fine 
motor skills in lower extremities were improved, and 
both cardiorespiratory and aerobic endurance in-
creased. The quality and distance of ambulation was 
also improved. The patient was now able to walk 224 
meters with a standard walker during the 6MWT. The 
pain level decreased by 6 points as per VAS. At dis-
charge from the rehabilitation center, the Balance + 
Gait score of the Tinetti Gait and Balance Assessment 
Tool was 21/28. Summary of the major benefits to the 
patient assessed post 30-day rehabilitation period is 
presented in Table 3.
Bimonthly neurological post-rehabilitation evalua-
tions using the ALSFRS-R showed the score drop 
from 28 to 24, 23 and 22 within the first two, four and 
Fig. 2. Pre- vs. post-treatment changes in the amplitudes 
of the given waves for the respective leads in quantitative 
EEG analyses.
Fig. 3. Pre- vs. post-treatment changes in the amplitudes 
of SMR waves for the respective leads in quantitative 
EEG analyses.
SMR = sensorimotor rhythm
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six post-transplantation months, respectively, then the 
score rose slightly to 23 and remained at this level for 
the next six months, indicating that the disease rate 
was decelerated, as illustrated in Figure 1. The score 
drop immediately following SCT could be attributed 
to the postoperative inflammatory reaction, which had 
an effect on the patient’s daily functioning. The score 
increase during the post-rehabilitation period resulted 
mainly from improvement in walking and reduced 
dyspnea, which allowed the patient to sleep with less 
pillow support. The patient continued to undergo bi-
monthly evaluations by the leading neurologist in or-
der to monitor the overall effects of the SCT and com-
plex rehabilitation. Based on the post-hospitalization 
interviews, it was also noted that the supporting role of 
the family and social environment could not be under-
estimated, since it clearly plays an important role in 
maintaining patient interests in daily life and helps 
motivate patients to continue the recommended exer-
cises.
Discussion
To the best of our knowledge, this is the first report 
of a complex rehabilitation protocol including NFB in 
the ALS patient having undergone single SCT that 
resulted in improved ALSFRS-R score, then remain-
ing stable for at least six months. Although in this case 
most if not all components of the applied therapies 
contributed to the successful rehabilitation process, it 
should be stressed that introducing the NFB treat-
ment at the time when the patient started to show 
signs of a quickly-deepening depression and refused to 
continue rehabilitation was likely a critical turning 
point in the post-transplantation period. Relatively 
quickly achieved alertness and stress reduction result-
ed in the patient’s visibly improved mood, consider-
ably improved communication and cooperation with 
therapists and increased motivation to continue physi-
cal therapy, which certainly made the entire rehabilita-
tion process far more effective.
Depression is a very serious problem in ALS, and 
antidepressant use is more common in patients with 
ALS than in controls, especially during the year prior 
to diagnosis10. This most recently reported observation 
is very significant, since it suggests that certain mo-
lecular manifestations of early neuro- and/or neuroim-
mune degenerative processes may become signals de-
coded by the brain’s deciphering machinery, and then 
transformed into the conscious perception level as a 
feeling of depression. Perhaps this new finding will in-
spire search for these depression-related phenomena 
as the potential early markers of ALS and maybe of 
other neurodegenerative disorders.
Since immune dysregulation is one of the major 
pathophysiology elements underlying ALS31-35, it is 
tempting to speculate that the neuromodulatory ef-
fects of NFB may actually synergize with the immu-
nomodulatory activities of the transplanted stem cells, 
and thus generated neuroimmune modulation may 
enhance therapeutic potential of the stem cells alone. 
So, as the psycho-neuro-immunology is gaining atten-
tion as a subject of clinical research36-38, NFB may ac-
Table 3. Summary of major benefits for the patient 




/ score before 
therapy 
Patient status  
/ score following 
therapy
Visual analog scale 
(VAS) 9/10 3/10
Six-minute walk test 
(6MWT) 192 meters 224 meters
Hamilton Rating 
Scale for Depression 
(HRS)
17/58 6/58
Barthel ADL index 7/20 15/20
EEG 
Neurofeedback: 
amplitudes of SMR 




amplitudes of SMR 
wave in the C4 point
6.33 6.84
Measure of state 
anxiety sten 4/10 sten 3/10
Executive functions CTT1 - ten 
43/100;
CTT2 - ten 
31/100
CTT1 - ten 
46/100;
CTT2 - ten 
34/100
Tinetti Gait and Balance Assessment Tool
Gait score 8/12 9/12
Balance score 8/16 12/16
Total score: balance 
+ gait 16/28 21/28
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tually be a very helpful tool assisting in regulating and 
organizing this enormously convoluted cross-road. At 
any rate, studies exploring the potential neuroimmune 
modulatory effects of NFB in different clinical settings 
should expand our still very limited understanding of 
the psycho-neuro-immune connections.
Our patient could be described as a ‘responder’ to 
the SCT and to the individually designed complex re-
habilitation protocol including NFB sessions. The flail 
arm syndrome variant of ALS has a slower progression 
rate and significantly better survival than typical 
ALS39, and it will be important to determine the ef-
fectiveness of NFB as supportive therapy in other ALS 
phenotypes, and in a larger ALS patient population.
Conclusion
As the explorations of stem cell types and protocols 
for single and multiple transplantations continue, par-
allel efforts aiming at the development of companion 
complex rehabilitation therapies that would turn ther-
apeutic benefits gained through SCT into the long-
lasting effects should deliver new ALS treatment op-
tions and allow the disease control.
The brain-computer interfaces have already been 
proven suitable to either expand our understanding of 
the motoneuron degeneration or showed potential of a 
positive impact focusing on certain deficits in ALS40,41. 
Based on our experience reported here, we conclude 
that NFB can be used as neurorehabilitation therapy 
supporting individually designed physiotherapy, and 
may therefore deliver a much sought-after quality of 
life-improving therapy in the ALS care.
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Sažetak
SLOŽEN PROTOKOL LIJEČENJA BOLESNIKA  
S AMIOTROFIČNOM LATERALNOM SKLEROZOM
J. Białkowska, D. Mroczkowska, M. E. Huflejt, J. Wojtkiewicz, T. Siwek, M. Barczewska i W. Maksymowicz
Amiotrofična lateralna skleroza je progresivna i smrtonosna degenerativna neuromuskularna bolest za koju postoji malo, 
ako uopće ijedna mogućnost liječenja pa je najčešći oblik terapije fizikalna rehabilitacija usmjerena na točno određene nedo-
statke. Ovi bolesnici pate i od depresije te pojačane anksioznosti. Cilj istraživanja bio je procijeniti učinkovitost neuroreha-
bilitacije u bolesnika s amiotrofičnom lateralnom sklerozom koji je podvrgnut transplantaciji matičnih stanica, ali je zbog 
depresije odbio fizikalnu terapiju. Progresija bolesti praćena je pomoću revidirane Ljestvice za funkcionalnu ocjenu amiotro-
fične lateralne skleroze svaka dva mjeseca kroz šest mjeseci prije te nakon transplantacije matičnih stanica. Psihološke zna-
čajke procjenjivane su pomoću šest standardiziranih testova. Kvantitativna elektroencefalografska dijagnostika provedena je 
prije prvog i nakon posljednjeg neurofeedback tretmana, koji su se provodili tri puta na tjedan. Protokol fizikalne terapije 
obuhvaćao je, među ostalim, proprioceptivnu neuromuskularnu facilitaciju, jedinicu električnih modaliteta primijenjenu u 
području lumbalne kralježnice te vježbe disanja, opuštanja i hodanja. Pojačana motivacija i znatno sniženje razine boli bili su 
udruženi s bolesnikovim pristankom na potpunu fizikalnu terapiju, što je rezultiralo poboljšanjem većine neuromuskularnih 
nedostataka i povećanim dišnim kapacitetom. Tijekom 12 mjeseci nakon rehabilitacije progresija bolesti se usporila i zabilje-
žena je pozitivna promjena ponašanja. Ovo istraživanje je pokazalo da se neurofeedback može primijeniti kao neurorehabili-
tacijska sastavnica personaliziranog složenog protokola rehabilitacije u bolesnika s amiotrofičnom lateralnom sklerozom.
Ključne riječi: Biološka povratna sprega, psihologija; Amiotrofična lateralna skleroza; Depresija; Kvaliteta života
